Cerus Corporation
An American biotechnology company developing pathogen-reduction systems for donated blood components.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Cerus Corporation is an American biotechnology company headquartered in Concord, California, whose business is centered on blood safety and the reduction of transfusion-transmitted pathogens. Its principal commercial platform is the INTERCEPT Blood System, a treatment technology designed for certain donated blood components, especially plasma and platelets. The system uses the company’s Helinx technology, in which a photoactive compound and ultraviolet-A illumination are used to damage the nucleic acids of pathogens. Because the treated blood components do not rely on intact DNA or RNA for their therapeutic function, the process is intended to reduce the ability of viruses, bacteria, and other microorganisms to replicate while preserving the clinical utility of the plasma or platelets. The company’s origins date to the AIDS epidemic of the 1980s. Hematologist Laurence Corash developed an approach for using ultraviolet light to inactivate HIV in donated plasma and continued the work with colleagues associated with the University of California, San Francisco School of Medicine. Corash and chemist John E. Hearst founded Cerus Technologies Inc. on September 19, 1991. The company later adopted the Cerus Corporation name, which appeared in its initial 1996 Securities and Exchange Commission filing. Cerus initially concentrated on plasma and platelet applications because these components are relatively translucent and can be exposed to ultraviolet light more readily than red blood cells. The Helinx process was incorporated into the INTERCEPT Platelet blood-screening system in 2001. Cerus entered a commercialization arrangement with Baxter International to pursue European marketing and regulatory approvals, and it subsequently obtained European certification for platelet and plasma applications. In 2006, Cerus acquired Baxter’s remaining shared commercial rights to the INTERCEPT system for plasma and platelets. The company also explored extending pathogen reduction to red blood cells, a technically more difficult application because their opacity limits light penetration. INTERCEPT Platelets received European CE Mark Class III certification in 2002, while INTERCEPT Plasma received European certification in 2006. In the United States, the Food and Drug Administration approved the platelet and plasma systems in December 2014. The platelet authorization was expanded in 2016 to include platelets suspended in 100% plasma. The company has also pursued market and commercialization relationships outside the United States, including an arrangement with Grifols for blood-center marketing and operation in Spain and Portugal. Cerus presents pathogen reduction as a complement to donor screening and testing rather than as a universal replacement for those safeguards. The technology has been studied against a range of clinically important viruses, including HIV, hepatitis B, hepatitis C, West Nile virus, Zika virus, dengue virus, SARS-related coronaviruses, and MERS coronavirus, as well as selected bacterial organisms. It does not neutralize every possible pathogen equally; some organisms, including certain non-enveloped viruses and bacterial spores, can be more resistant to the process. Consequently, the system’s effectiveness depends on the pathogen, component, treatment conditions, and regulatory indication. The company’s products have been used or evaluated in humanitarian, epidemic-response, and investigational settings. During the 2016 Zika outbreak, INTERCEPT technology was supplied to a designated blood center in Rio de Janeiro in connection with efforts to protect the blood supply during the Olympic Games. During the COVID-19 pandemic, the FDA authorized emergency use of INTERCEPT to treat convalescent plasma collected from recovered patients for investigational antibody-based transfusion therapy. Cerus has also been involved in research involving Ebola survivor plasma and platelet-related applications in regions affected by dengue and chikungunya. Cerus operates in a specialized medical-device and biotechnology niche. Adoption varies by market because pathogen reduction adds processing costs and requires compatible collection, treatment, and storage infrastructure. European and selected international healthcare systems have provided important markets and clinical-use settings, while adoption in the United States has faced the economic challenge of adding treatment expense to a blood supply that already benefits from extensive donor screening and laboratory testing. The company’s strategic focus remains the development, regulatory approval, commercialization, and clinical expansion of blood-component pathogen-reduction technologies.
History
Cerus Corporation emerged from research conducted in response to the transfusion risks highlighted by the AIDS epidemic. In the mid-1980s, hematologist Laurence Corash developed a method intended to inactivate HIV particles in donated blood plasma with ultraviolet light. He continued developing prototypes with colleagues connected to the University of California, San Francisco School of Medicine. Chemist John E. Hearst later joined the effort, and the two researchers founded Cerus Technologies Inc. on September 19, 1991. The company was subsequently renamed Cerus Corporation; that name was used in its first 1996 SEC filing. The underlying technology became known as Helinx. It was designed around treating blood components outside the body rather than administering a pathogen-inactivating chemical directly to a patient. A photoactive compound is added to a donation and activated using ultraviolet-A light. The process damages pathogen DNA or RNA, preventing replication. Plasma and platelets were early targets because their translucency permits the treatment light to reach a substantial portion of the component. Red blood cells presented a more difficult engineering problem because their density and opacity interfere with light transmission. By December 2001, Cerus had incorporated Helinx into a medical device known as the INTERCEPT Platelet blood-screening system. The company entered into a commercialization agreement with Baxter International to pursue European marketing and regulatory approvals. INTERCEPT Platelets received European CE Mark Class III certification in 2002. In 2005, the platelet certification was renewed with a modification permitting storage for seven days instead of the previous five-day period. Cerus later obtained European certification for INTERCEPT Plasma on November 21, 2006, and received ISO 13485 certification for its plasma and platelet products during the same year. The relationship with Baxter changed in 2006, when Cerus announced that it had acquired Baxter’s shared commercial rights to the INTERCEPT blood system for plasma and platelets. This gave Cerus greater control over commercialization of its core platform. The company also pursued additional geographic arrangements, including a later agreement with Grifols to market and operate the products in blood centers in Spain and Portugal. United States regulatory progress came later. The FDA granted premarket approval for INTERCEPT Platelets on December 18, 2014, and for INTERCEPT Plasma on December 16, 2014. On March 10, 2016, the platelet approval was modified to include platelets suspended in 100% plasma. These authorizations established a US regulatory pathway for the company’s principal products, although commercial adoption has been influenced by processing costs, blood-center equipment, existing donor-screening systems, and the economics of transfusion services. Cerus has promoted the technology as capable of addressing both recognized and emerging infectious threats. Studies and clinical work have examined applications involving HIV, hepatitis B, hepatitis C, West Nile virus, Zika, dengue, SARS-related viruses, MERS coronavirus, and bacterial contamination. The process is not universally effective against every microorganism. Some pathogens, including hepatitis A, human parvovirus B19, and certain bacterial spores, may be more resistant, so pathogen reduction remains one component of a broader blood-safety framework. The company’s technology has also been used in outbreak-response and investigational contexts. In 2016, during the Zika epidemic, an INTERCEPT system was supplied to a designated blood center in Rio de Janeiro in connection with efforts to maintain a safe blood supply during the Olympic Games. Cerus-supported research has included treatment of convalescent plasma from Ebola survivors in West Africa and at Emory University, as well as platelet-related work in Puerto Rico, where dengue and chikungunya were public-health concerns. On August 23, 2020, amid the COVID-19 pandemic, the FDA granted emergency use authorization for INTERCEPT treatment of donated COVID-19 convalescent plasma intended for investigational antibody-immunotherapy transfusions. Cerus therefore developed from an infectious-disease research venture into a specialized public biotechnology company serving transfusion medicine. Its principal commercial identity remains tied to the INTERCEPT Blood System and to the broader goal of reducing pathogen transmission through treated plasma and platelet products. Market conditions differ substantially by country: some European and international settings have adopted or evaluated the systems, while the US market has faced cost and infrastructure barriers because conventional testing already supports a large supply of screened blood components.
- 2020
Emergency authorization for COVID-19 convalescent plasma
[1]The FDA authorizes emergency use of INTERCEPT for treating donated convalescent plasma from recovered COVID-19 patients for investigational transfusion therapy.
- 2016
US platelet indication is expanded
[1]The FDA expands the platelet authorization to include platelets suspended in 100% plasma.
- 2014
US FDA approvals for platelet and plasma systems
[1]The FDA grants premarket approval to INTERCEPT Platelets and INTERCEPT Plasma in December.
- 2006
Plasma certification and Baxter rights acquisition
[1]INTERCEPT Plasma receives European certification, and Cerus acquires Baxter’s shared commercial rights for the INTERCEPT plasma and platelet systems.
- 2005
Platelet storage indication is extended
[1]The European platelet certification is modified to permit seven-day storage rather than five-day storage.
- 2002
European certification for INTERCEPT Platelets
[1]INTERCEPT Platelets receives European CE Mark Class III certification.
- 2001
Helinx is incorporated into INTERCEPT Platelets
[1]Cerus incorporates its pathogen-reduction process into the INTERCEPT Platelet blood-screening system.
- 1996
Cerus Corporation name appears in SEC filing
[1]The company uses the Cerus Corporation name in its initial SEC filing.
- 1991
Cerus Technologies is founded
[1]Laurence Corash and John E. Hearst establish Cerus Technologies Inc. on September 19.
- 1980
Early Helinx research begins
[1]Laurence Corash develops an ultraviolet-light approach intended to inactivate HIV in donated plasma during the AIDS epidemic.
Products and positioning
Specialist blood-safety biotechnology company focused on pathogen reduction in transfusion medicine.
Blood-component pathogen-reduction system · 2001
INTERCEPT Blood System
Cerus’s principal commercial platform for reducing pathogens in selected donated blood components. The system applies the Helinx process outside the body, using a photoactive compound and ultraviolet-A illumination to damage pathogen DNA or RNA. It is designed for use with components such as plasma and platelets, while remaining compatible with their intended transfusion use. The system is a risk-reduction technology and is not universally effective against every pathogen.
Platelet pathogen-reduction product · 2001
INTERCEPT Platelets
The platelet-focused INTERCEPT application treats donated platelet components to reduce the replication capability of susceptible viruses and bacteria. It received European CE Mark Class III certification in 2002 and US FDA premarket approval in 2014. The European indication was later modified to support seven-day platelet storage, and the US authorization was expanded in 2016 to include platelets suspended in 100% plasma.
Plasma pathogen-reduction product · 2006
INTERCEPT Plasma
The plasma application of the INTERCEPT platform is intended to reduce pathogens in donated plasma before transfusion. It received European CE Mark certification in 2006 and US FDA premarket approval in December 2014. The system has also been used in investigational and emergency-response contexts, including treatment of convalescent plasma during the COVID-19 pandemic.
Pathogen-inactivation technology
Helinx
Helinx is Cerus’s proprietary pathogen-reduction technology underlying the INTERCEPT platform. It combines a treatment compound with ultraviolet-A light to disrupt pathogen nucleic acids. The approach was initially conceived for HIV risk reduction in plasma and was later developed for broader applications involving viruses and bacteria in donated blood components.
Marketing campaigns
- 2020COVID-19 convalescent-plasma response
United States
Cerus pursued use of INTERCEPT to treat convalescent plasma collected from people who had recovered from COVID-19. The objective was to reduce pathogens in plasma intended for investigational antibody-based transfusion therapy.
Outcome. The FDA issued emergency use authorization on August 23, 2020, allowing the treatment in the specified investigational context.
- 2016Rio 2016 blood-safety response
Brazil
During the Zika outbreak, Cerus supplied INTERCEPT technology to a designated blood center in Rio de Janeiro. The application supported efforts to protect blood supplies associated with the city and the 2016 Olympic Games.
Outcome. The technology was deployed in a high-profile outbreak-response and event-related blood-safety setting.
- Ebola survivor plasma research
West Africa · United States
Cerus’s INTERCEPT technology was evaluated in work involving convalescent plasma donated by Ebola survivors, including research in West Africa and at Emory University.
Outcome. The work remained an investigational and clinical-research application rather than a stated universal treatment indication.
Brand decisions
2020
Emergency-use expansion during COVID-19OtherBackground
The COVID-19 pandemic generated interest in convalescent plasma as an investigational therapy and raised additional concerns about the safety of donated plasma.
Action taken
Cerus obtained FDA emergency use authorization for INTERCEPT treatment of donated COVID-19 convalescent plasma.
Aftermath
The authorization enabled use in the specified investigational setting, while the broader clinical value of convalescent-plasma treatment remained subject to medical debate.
2014
US commercialization of INTERCEPT Platelets and PlasmaProduct launchBackground
After obtaining European certifications, Cerus pursued US regulatory clearance for its two principal blood-component applications.
Action taken
The FDA granted premarket approval for INTERCEPT Platelets and INTERCEPT Plasma in December 2014.
Aftermath
The approvals created a US regulatory basis for commercialization, although adoption remained affected by blood-center economics and processing requirements.
2006
Acquisition of Baxter’s shared INTERCEPT rightsM&ABackground
Cerus had previously worked with Baxter to commercialize the INTERCEPT systems in Europe.
Action taken
Cerus acquired all of Baxter’s shared commercial rights to the INTERCEPT blood system for plasma and platelets.
Aftermath
The transaction gave Cerus greater control over the commercialization of its core blood-safety platform.
2006
Expansion toward red-blood-cell applicationsStrategyBackground
Cerus’s initial applications focused on plasma and platelets, while red blood cells were more difficult to treat because their opacity limits ultraviolet-light penetration.
Action taken
The company announced work to extend its pathogen-reduction system to red blood cells.
Aftermath
The effort reflected an attempt to broaden Cerus’s addressable transfusion-medicine market beyond plasma and platelets.
2001
Launch of the INTERCEPT Platelet systemProduct launchBackground
Cerus sought to move its Helinx research from laboratory prototypes into a transfusion-medicine product capable of treating donated platelets outside the body.
Action taken
The company incorporated Helinx into the INTERCEPT Platelet blood-screening system and entered a commercialization agreement with Baxter for European market development and regulatory work.
Aftermath
The product became the foundation of Cerus’s later regulatory approvals and commercial strategy.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cerus-corporation · Editorial policy · How profiles are compiled